TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909.
Kim Y, Girardi M, Duvic M, Kuzel T, Rook A, Link B, Pinter-Brown L, Comerci C, McAuley S, Schmalbach T. TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909. Blood 2004, 104: 743. DOI: 10.1182/blood.v104.11.743.743.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaCPG 7909Progressive diseaseClinical responseStable diseasePartial responseComplete responseAdvanced cutaneous T-cell lymphomaModerate flu-like symptomsGlobal assessmentLocal injection site reactionsCTC grade 1More systemic therapiesObjective clinical responsesPhysician global assessmentDurability of responseFlu-like symptomsInjection site reactionsNK cell functionPhase II portionWeeks of treatmentResults of patientsT-cell lymphomaGamma-glutamyl transferaseImmunomodulator treatment